Variables | Total | Renal vein thrombus | IVC thrombus | P value |
---|---|---|---|---|
N (%) | 86 | 53(61.6) | 33(38.4) | |
Age, year | 57.7 ± 11.3 | 57.1 ± 11.5 | 58.7 ± 11.2 | 0.535 |
Gender (%) | ||||
Male | 58(67.4) | 35(66) | 23(69.7) | 0.725 |
Female | 28(32.6) | 18(34) | 10(30.3) | |
Laterality (%) | ||||
Left | 39(45.3) | 27(50.9) | 12(36.4) | 0.187 |
Right | 47(54.7) | 26(49.1) | 21(63.6) | |
Clinical symptom (%) | ||||
Yes | 47(54.7) | 26(49.1) | 21(63.6) | 0.187 |
No | 39(45.3) | 27(50.9) | 12(36.4) | |
Tumor size, cm | 8.2 ± 2.4 | 8.1 ± 2.2 | 8.3 ± 2.5 | 0.731 |
ECOG-PS | 0.8 ± 0.8 | 0.6 ± 0.8 | 1.2 ± 0.7 | 0.04 |
Histological type (%) | ||||
Clear cell | 67(77.9) | 43(81.1) | 24(72.7) | 0.361 |
Others | 19(22.1) | 10(18.9) | 9(27.3) | |
Tumor grade (%) | ||||
G1 | 6(7.0) | 6(11.3) | 0(0) | |
G2 | 38(44.2) | 24(45.3) | 14(42.4) | 0.156 |
G3 | 33(38.4) | 19(35.8) | 14(42.4) | |
G4 | 9(10.5) | 4(7.5) | 5(15.2) | |
T stage (%) | ||||
T3a | 50(58.1) | 49(92.5) | 0(0) | |
T3b | 17(19.8) | 0(0) | 18(54.5) | 0.000 |
T3c | 10(11.6) | 0(0) | 10(30.3) | |
T4 | 9(10.5) | 4(7.5) | 5(15.2) | |
N stage (%) | ||||
N0 or Nx | 70(81.4) | 45(84.9) | 25(75.8) | 0.289 |
N1 | 16(18.6) | 8(15.1) | 8(24.2) | |
M stage (%) | ||||
M0 | 75(87.2) | 50(94.3) | 25(75.8) | 0.029 |
M1 | 11(12.8) | 3(5.7) | 8(24.2) | |
Perinephric fat invasion (%) | ||||
Yes | 31(36.0) | 11(20.8) | 20(60.6) | 0.000 |
No | 55(64.0) | 42(79.2) | 13(39.4) | |
Renal pelvis invasion (%) | ||||
Yes | 10(11.6) | 5(9.4) | 5(15.2) | 0.647 |
No | 76(88.4) | 48(90.6) | 28(84.8) | |
Thrombus level (%) | ||||
Renal vein | 53(61.6) | 53(100) | 0(0) | |
I | 16(18.6) | 0(0) | 16(48.5) | 0.000 |
II | 11(12.8) | 0(0) | 11(33.3) | |
III | 6(7.0) | 0(0) | 6(18.2) | |
Invasion of IVC wall (%) | ||||
Yes | 12(14.0) | 0(0) | 12(36.4) | 0.000 |
No | 74(86.0) | 53(100) | 21(63.6) | |
Neoadjuvant-molecular-targeted therapy (%) | ||||
Yes | 2(2.3) | 0(0) | 2(6.1) | 0.144 |
No | 84(97.7) | 53(100) | 31(93.9) |